| Post | Subject | | |
|
#682
|
Depends, you have to look at the coverage
|
Tanis2476
| 09/22/17 09:42:51 AM |
|
#681
|
Is the real problem that PCPs are reluctant
|
north40000
| 09/20/17 10:01:47 AM |
|
#680
|
Pfizer (NYSE:PFE) today filed suit in the U.S.
|
corpus
| 09/20/17 09:24:32 AM |
|
#679
|
JNJ throws in the towel on HCV: #msg-134514481.
|
DewDiligence
| 09/11/17 06:18:37 AM |
|
#678
|
This news was out midday and had no
|
chriswolff
| 08/22/17 05:36:00 AM |
|
#677
|
lol good spot. you got this one
|
pennystockaholic
| 08/13/17 05:03:23 PM |
|
#676
|
NO More Pricks!!!
|
Trend-Setter
| 08/11/17 08:58:18 AM |
|
#675
|
Breakthrough in vaccine delivery will disrupt the vaccine industry.
|
Trend-Setter
| 08/11/17 08:58:18 AM |
|
#674
|
Very slim chance especially for Safety Issues.
|
Trend-Setter
| 08/10/17 12:05:44 PM |
|
#673
|
No update yet. The FDA decision will come
|
DewDiligence
| 08/09/17 08:42:49 PM |
|
#672
|
Any updates yet ? Or CC's
|
pennystockaholic
| 08/09/17 08:37:42 PM |
|
#671
|
https://seekingalpha.com/article/4095791-johnson-and-johnson-receives-massive-no
|
Inoviorulez
| 08/07/17 04:55:21 PM |
|
#670
|
FDA advisory panel rejects sirukumab:
|
DewDiligence
| 08/02/17 07:08:56 PM |
|
#669
|
FDA briefing docs for JNJ’s sirukumab:
|
DewDiligence
| 07/31/17 11:07:59 AM |
|
#668
|
DECN has beaten and will continue to beat
|
zoran
| 07/27/17 08:17:06 AM |
|
#667
|
MRK/Samsung—Renflexis FoB priced at 35% discount to branded Remicade:
|
DewDiligence
| 07/24/17 11:04:15 AM |
|
#666
|
Thanks sir
|
pennystockaholic
| 07/20/17 05:12:12 PM |
|
#665
|
JNJ 2Q17 CC slides:
|
DewDiligence
| 07/18/17 04:49:14 PM |
|
#664
|
Decode today's JNJ earnings: http://alph.st/b6961241
|
raff
| 07/18/17 04:11:41 PM |
|
#663
|
Decode today's JNJ earnings: http://alph.st/b6961241
|
raff
| 07/18/17 04:11:39 PM |
|
#662
|
https://seekingalpha.com/article/4088182-johnson-and-johnson-approval-tremfya-hu
|
Inoviorulez
| 07/17/17 03:04:27 PM |
|
#661
|
FDA approves Tremfya (guselkumab) for psoriasis:
|
DewDiligence
| 07/13/17 06:43:57 PM |
|
#660
|
Hire a vet. yet injure thousands of people.
|
nonsequetor
| 07/03/17 05:12:23 PM |
|
#659
|
Alex Gorsky's comments on hiring veterans will make
|
pumper_stumper
| 07/03/17 03:32:24 PM |
|
#658
|
The salient point is that it doesn't appear
|
DewDiligence
| 06/26/17 03:53:36 PM |
|
#656
|
I'm new to this forum so I'm looking
|
Gabridge
| 06/26/17 03:10:33 PM |
|
#655
|
Amputations, Hip Replacement Failures, Baby Powder Problems...
|
nonsequetor
| 06/24/17 10:45:04 AM |
|
#654
|
Jardiance does have not the amputation side effect
|
DewDiligence
| 06/21/17 07:33:14 PM |
|
#653
|
JNJ , if they are quick, could purchase
|
stealthways
| 06/21/17 11:38:12 AM |
|
#652
|
JNJ cruising. Glad I have a large position here.
|
no shorts
| 06/16/17 09:41:37 AM |
|
#651
|
Invokana CVOT shows surprising, troublesome side effect: #msg-132119932.
|
DewDiligence
| 06/12/17 06:43:51 PM |
|
#650
|
Chart:
|
nonsequetor
| 06/12/17 12:47:03 PM |
|
#649
|
The Nevada case may come to fruition later
|
Johnny_C
| 06/07/17 09:12:27 AM |
|
#648
|
Better Vaccines For The Future...
|
Trend-Setter
| 06/05/17 02:22:46 AM |
|
#647
|
New Highs Ahead?
|
nonsequetor
| 05/31/17 01:01:14 PM |
|
#645
|
Making comparisons between JNJ and DECN is not
|
nonsequetor
| 05/21/17 02:24:21 PM |
|
#644
|
JNJ buy option 126.78
|
stocktrademan
| 05/19/17 01:56:18 PM |
|
#643
|
J&J's so called "competitor" DECN, just closed at
|
pumper_stumper
| 05/18/17 04:16:57 PM |
|
#642
|
FDA warns of foot, leg amputations with J&J
|
nonsequetor
| 05/18/17 02:17:53 PM |
|
#641
|
https://seekingalpha.com/news/3268081-j-and-js-gorsky-amazon-potential-foray-pharmaceuticals-good-th
|
north40000
| 05/17/17 09:06:55 AM |
|
#640
|
JNJ: J.P. Morgan analyst raises JNJ price target
|
north40000
| 05/16/17 04:49:35 PM |
|
#639
|
Finding a new home base?
|
nonsequetor
| 05/13/17 11:54:47 AM |
|
#638
|
DECN Subsidiaries File Amended Complaint Against Jonhson &
|
nonsequetor
| 05/04/17 09:43:17 AM |
|
#637
|
On April 27, 2017, the company announced that
|
nonsequetor
| 05/03/17 12:01:03 PM |
|
#636
|
I don't think a 6-week HCV regimen will
|
DewDiligence
| 04/25/17 02:13:42 PM |
|
#635
|
Does the cost really justify a difference of
|
nonsequetor
| 04/25/17 01:43:21 PM |
|
#634
|
More discussion on JNJ/ACHN's HCV regimen: #msg-130785673.
|
DewDiligence
| 04/25/17 12:53:38 PM |
|
#633
|
JNJ/ACHN’s 3-DAA HCV regimen has a problem: #msg-130712374.
|
DewDiligence
| 04/22/17 11:58:01 AM |
|
#632
|
Johnson & Johnson (NYSE:JNJ) Drops After Earnings
|
ITMS
| 04/20/17 11:14:36 AM |
|
#631
|
JNJ -3% on soft 1Q17 results: #msg-130570965.
|
DewDiligence
| 04/18/17 11:53:33 AM |
| Post | Subject | | |